Background. Nucleic acid microarray (NAM) testing for detection of Staphylococcus aureus bacteremia (SAB) and S. aureus resistance gene determinants can reduce time to targeted antibiotic administration. Evidence-based management of SAB includes bedside infectious diseases (ID) consultation. As a healthcare improvement initiative at our institution, with the goal of improving management and outcomes for subjects with SAB, we implemented NAM with a process for responding to positive NAM results by directly triggered, mandatory ID consultation.
Management is improved and mortality reduced when an infectious diseases (ID) specialist is consulted for management of SAB [1, [20] [21] [22] [23] [24] [25] . Physician bedside consultation, rather than phone intervention, may be required to achieve observed mortality improvements [26] . At our institution, SAB was diagnosed by traditional culture methods and results passively transmitted to an ASP team member for referral to optional ID consultation. We sought to improve management and outcomes for patients with SAB at our institution and implemented NAM together with a process for responding to NAM results by immediate ID consultation. The ASP pharmacist was involved following initial consultation. We hypothesized that the new, rapid diagnosis and direct response process would result in earlier ID consultation, shorter time to targeted antibiotics, and improved outcomes.
METHODS

Study Design
A pre-/postintervention, retrospective study of this healthcare improvement intervention was implemented. Pre-and postintervention data were collected retrospectively. The Institutional Review Board at the University of Virginia (UVA) approved the protocol as a quality improvement project. Inpatients at UVA Medical Center, >18 years old, with at least 1 blood culture positive for S. aureus between December 2012 and July 2015 were included in the analysis. Subjects were excluded from analysis if they received a palliative care consult resulting in a change to comfort-focused management during their inpatient admission, had polymicrobial bacteremia, received their initial diagnosis of SAB at another institution prior to transfer to UVA, or represented a repeat episode of SAB during a single hospital stay.
Blood Culture and Nucleic Acid Microarray
Microbiologic testing was performed at the UVA clinical microbiology laboratory. Throughout both intervention periods, a standard Gram stain was performed on blood culture samples that alerted positive from BacT/Alert FA (bioMérieux, Durham, North Carolina) and treated as a critical result requiring a telephone call to the primary patient care team.
Preintervention, peptide nucleic acid fluorescent in situ hybridization (PNA-FISH) (AdvanDX, Woburn, Massachusetts) was performed on specimens showing gram-positive cocci in clusters. PNA-FISH differentiates S. aureus from coagulase-negative Staphylococcus species but does not differentiate methicillin-susceptible S. aureus (MSSA) from methicillin-resistant S. aureus (MRSA). The use of PNA-FISH on samples was batched twice daily on weekdays and daily on weekends rather than being performed for each sample at the time of positivity. Susceptibility testing was performed using the Vitek2 AST-GP75 card (bioMérieux).
Postintervention, Verigene BC-GP NAM assay was performed per the manufacturer's instructions and as described previously [12, 27] on all specimens showing gram-positive cocci. Total processing time for a NAM specimen was between 2 and 2.5 hours, consistent with other reports [28] . Specimens with polymicrobial Gram stains were excluded from NAM testing due to testing characteristics [10, 12] . Staphylococcus aureus is detected based on gyrB with a separate gene probe for detection of mecA [27] . Other gram-positive cocci are also detected by NAM, but data associated with these specimens were not analyzed in this study [11, 29] . NAM testing was not batched, but was performed at the time of positive Gram stain results. All results derived from NAM were confirmed by growth consistency, latex agglutination, and susceptibility testing.
Healthcare Improvement Bundle Implementation
Preintervention, following notification of gram-positive cocci on Gram stain by the microbiology laboratory technician, the primary inpatient management team would determine subsequent actions ( Figure 1A ). Species results from sterile body fluid cultures were passively conveyed to the ASP team by Theradoc (Premier, Salt Lake City, Utah). Upon return of additional information indicating S. aureus, either by batched PNA-FISH or identification by traditional methods, above, an ASP pharmacist or physician would call the managing team by phone if they had not yet contacted ID. During this phone call, the ASP team member would provide initial antibiotic suggestions and recommend an ID consult. If the recommendations were not followed, ASP would recontact the team and repeat the recommendation for a consult, resulting in an iterative and variable process.
Postintervention, a positive Gram stain with monomorphic, gram-positive cocci would trigger an immediate NAM assay ( Figure 1B) . The microbiology laboratory technician reading a NAM result positive for S. aureus would page the on-call ID fellow (24 hours per day, 7 days per week), and the ID fellow would notify the primary team of the result. Upon calling the primary team, the fellow would recommend changes in antibiotics, and a mandatory (approved by the chief medical officer for the hospital) ID consultation order would be placed in the electronic health record (EHR). The ID fellow then performed a bedside consult using a standardized management bundle consistent with that described by López-Cortés et al [25] . Although ASP team members were not involved in this rapid diagnosis and direct response process ( Figure 1B ), they were involved in subsequent patient care during rounds for the rest of patient consultation. The ID consult was staffed by the ID attending after completion.
An evidence-based response bundle [25] included consideration of targeted antibiotics, repeat blood cultures for documentation of clearance, echocardiography (preferentially transesophageal), early source control, duration of therapy, and documentation of recommendations in a standardized EHRbased note. Management decisions were left to board-certified ID physicians. An educational program for this initiative included a didactic lecture for the internal medicine residents, education at ID faculty meetings, and integration of SAB management and healthcare improvement into the ID clinical training program for fellows.
Data Collection and Outcomes Analysis
We evaluated time to antibiotics, time to consultation, metrics related to management of SAB, and outcomes including mortality. Data derived from individual chart review included subject demographics, consultation time and duration, type and time of antibiotics administered, blood culture data, information related to the source of infection, echocardiography results, and outcomes. Charlson comorbidity index was calculated based on EHR coding. Antibiotic start and stop times were determined using the medication administration record and were crosschecked with notes in the EHR. Time of ID consultation was determined by initiation time of consult note in the EHR. For outcomes data, all patients were accounted for through the medical record at discharge and at 30 days.
Definition of uncomplicated bacteremia required no fever at 72 hours, no growth in blood cultures at 48-96 hours, no implanted prostheses, removal of central venous catheters and other intravascular devices, no metastatic sites of infection, clinical exclusion of endocarditis, negative echocardiographic investigation, and that bacteremia not be community acquired [20, 30, 31] . The type of echocardiography (transthoracic or transesophageal) was not specified in this definition. Infectious endocarditis was diagnosed based on the Modified Duke Criteria [32] . Notes of the ID team, or primary team if ID was not involved, were used to define the primary clinical focus of infection. If no focus of infection was identified in notes during the patient's inpatient admission or follow-up, the source of SAB was considered unknown and the bacteremia termed primary [33] .
Preferred, targeted antibiotics for management of SAB were defined by local institutional policy that was approved by ASP and the Pharmacy and Therapeutics Committee. For MSSA, the institutionally preferred antistaphylococcal (IPA) was nafcillin. If there was documented concern for toxicity, intolerance, or allergy to nafcillin, then cefazolin was the IPA. If there was documented allergy or intolerance to both nafcillin and cefazolin, then vancomycin was the IPA. For MRSA with vancomycin minimum inhibitory concentration (MIC) ≤1 μg/mL, vancomycin was the IPA. If there was a documented allergy or intolerance to vancomycin, then daptomycin was the IPA. If there was a documented allergy or intolerance to vancomycin and daptomycin, then ceftaroline or linezolid was the IPA. For MRSA with vancomycin MIC = 2 μg/mL, if there had been poor clinical response to vancomycin, then daptomycin, and/or ceftaroline or linezolid were the IPA [34] .
Statistical Analysis
Microsoft Excel software was used for raw data collection, and SPSS version 23 software was used for data analysis. Minitab17 was used for visualization of data related to healthcare improvement. For categorical data, Pearson χ 2 and Fisher exact test were used. For continuous data, Student t test and Mann-Whitney test were used. P values ≤.05 were considered significant. A logistic regression model was constructed using variables deemed either clinically relevant or supported in the medical literature [13, [35] [36] [37] . Variables were allowed entry into the model at a significance of .10, and variables that achieved a significance <.05 were allowed to remain in the model. Backward stepwise processes were used to fit the final model.
RESULTS
A total of 226 cases of SAB were included in analysis, 106 (46.9%) before the initiation of NAM (preintervention) and 120 (53.1%) after (postintervention). Twenty-two subjects were excluded: 21 based on palliative care consultation with change to comfort-focused care (4 pre-and 17 postintervention), and 1 based on diagnosis of SAB at an outside facility (preintervention). Preintervention and postintervention groups showed similar demographics and baseline characteristics ( [14] [15] [16] [17] , and we asked whether the process of rapid testing with direct physician response (Figure 1 ) was associated with shorter time to IPA. Most subjects had already been started on active antibiotics within 24 hours of Gram stain results (97.5% postintervention and 94.3% preintervention, P = .199; Table 2 ); however, the percentage of subjects receiving IPA within 24 hours was significantly greater postintervention than preintervention, and the time from Gram stain result to IPA was shorter by a mean of 21.2 hours (10.6 postintervention vs 31.8 preintervention, P < .001; 95% confidence interval [CI] of difference, 31.4 to 11.0). To study subjects whose antibiotics were started subsequent to a diagnosis of SAB, subjects receiving IPA prior to Figure 2 ) with narrower control limits postintervention than preintervention, the process changes were associated with consistently faster time to IPA. In addition to understanding the effect of NAM on antibiotic management, a goal of process improvement was to increase the rate of ID consultation. There was an increase in the percentage of patients receiving ID consults following the intervention (85.4% to 96.5%, P = .004), though the baseline consultation percentage was high (Table 2) . Importantly, the time from Gram stain to ID consultation decreased postintervention compared with preintervention by 26.0 hours (49.2 vs 23.2, P < .001; 95% CI of difference, 45.1 to 7.1). If an ID consult had been performed prior to the blood culture that was positive for SAB, this subject was not included in the calculation as this consult was not likely to have been initiated in response to SAB. Although more total consults were performed postintervention vs preintervention (109 vs 82 consults), the total number of consult days were fewer (669 vs 712 days), and the consult time per patient was 2.6 days shorter (6.1 vs 8.7 days, P = .037). Together, these data suggest more efficient consultation.
The project included a bundle for management of SAB, and we recorded pertinent management endpoints (Table 3) . Of patients with complicated SAB, a lower percentage was treated with <4 weeks of antibiotics in the postintervention compared to the preintervention group (20.0% vs 32.3%, P = .035). In agreement with these duration-of-therapy data, outpatient parenteral antibiotic therapy was employed for more subjects post-than preintervention (77.5% vs 61.3%, P = .006). Despite the improvement in time to IPA and duration of antibiotic administration, there was no significant difference in time to removal of intravascular lines and devices, time from Gram stain to negative blood culture, related readmission, or total length of hospital stay. There was, however, lower in-hospital mortality (5.8% and 13.2%, P = .047) and 30-day mortality (8.3% and 17.9%, P = .025) postintervention compared with preintervention, respectively. A logistic regression model was constructed to evaluate the association of subject characteristics with 30-day mortality. Variables were chosen for model construction based on clinical practice and published association with mortality in the setting of SAB [13, [35] [36] [37] . The described model was statistically significant: χ 2 (4) = 28.865, P < .001, explaining 22.4% (Nagelkerke R 2 ) of the variance of 30-day mortality. The model correctly classified 98.5% of patients who survived, but was only able to correctly 
DISCUSSION
With the new rapid diagnosis and direct physician response process, we observed not only improvement in time to ID consultation and IPA for SAB, but also improvement in mortality. Similar to the data presented here, other studies have found that NAM does not reduce time to active antibiotics for SAB, but substantially improves time to optimal antibiotics [18, 38] ; nonetheless, previous studies have not identified a mortality benefit [14, 18] . In the study with the largest number (n = 280) of SAB specimens managed with NAM [18] , other gram-positive bacteria were also examined, and mortality at baseline and after intervention was unchanged and similar in magnitude to baseline mortality reported in this study (~15%). A recent, retrospective, pre-/ postintervention study of a standardized and guideline-driven pharmacist response to NAM included 84 patients with SAB [19] . As with other studies of NAM for management of SAB or other etiologies of bacteremia [14, 18, 39, 40] , NAM was implemented simultaneously with improvements in pharmacy-directed ASP, consistent with IDSA antimicrobial stewardship guideline recommendations for systems changes when implementing RDT [13] ; nonetheless, no mortality benefit was identified.
In the intervention described here, multiple systems changes were made: Batched PNA-FISH was replaced by real-time BC-GP testing; an optional ID consult program was replaced by mandatory ID consultation for SAB; and the existing passive, business-day ASP response was replaced by direct, round-theclock physician response. A major difference between this study and others is not the implementation of NAM but the response. Whereas other studies include an ASP-directed response to NAM, the intervention here included a bedside physician response, with involvement of ASP after the initial consultation. The new process was more efficient, with fewer steps from microbiologic data to bedside.
ID physicians responded favorably to this intervention, integrating it into care and sustaining the process change. The positive outcomes of the intervention, and more efficient consults for SAB, further motivated physicians to sustain change. Non-ID physicians have accepted mandatory consults, with the few refusals occurring early during process change.
This was a pre-/postintervention, retrospective, single-center study, and the interpretation must acknowledge the potential for unmeasured confounders. Even with no differences between pre-and postintervention group characteristics (Table 1) , the study design limits the ability to determine causality. In addition, the multifaceted intervention prevents identification of a single factor (or synergy between factors) that contributed most to the observed results. While this is the largest study of BC-GP for SAB to report patient outcomes, the sample size may still be statistically limiting. For example, mortality was lower postintervention but readmissions and length of stay were unchanged; discordance may be attributable to sample size or the complex clinical determinants of these different outcomes.
Ultimately, the aim of this project was not to identify the most important single factor involved in SAB care, but to improve quality of care by integrating antibiotic stewardship guidelines [13] with evidence-based practice for management of SAB. Similar organism-specific response processes may be appropriate for other gram-positive bacteria detected by NAM. More broadly, the study highlights the importance of applied research for guideline recommendations. 
